Abstract
Introduction:
Mycosis fungoides (MF) is the most common cutaneous lymphoma, accounting for 50% of all cutaneous lymphomas. Programmed death-1 (PD-1; CD279) is a marker of follicular helper T cells and is expressed by the neoplastic T cells of some types of malignant lymphoma, including MF. About 30% of primary cutaneous T-cell lymphomas are CD30 positive and have a broad spectrum from lymphomatoid papulosis to primary cutaneous anaplastic large cell lymphoma. CD30 expression in MF is important for diagnostic purposes, prognostic value, and a therapeutic perspective. In this study, PD-1 and CD30 expression in early MF lesions has been examined, and its relationship between prognosis and survival has been questioned. The byproducts could be unorthodox treatment options.
Methods:
We prospectively applied immunohistochemically CD30 and PD-1 antibodies to the biopsies at our institution. We statistically evaluated the relationship between the expression rates of CD30 and PD-1 in atypical lymphocytes, with recurrence and survival.
Results:
This research with 119 patients was able to show a statistically significant relationship between CD30 and recurrence with PD-1 and poor survival.
Conclusions:
When evaluated together with treatment options, CD30 and PD-1 are markers that may guide the clinical follow-up of aggressive MF cases.
Keywords: CD30 ligand, mycosis fungoides (MF), programmed cell death-1 receptor (PD-1)
